New Trends in the Field Triple-agonist therapies approaching weight loss levels previously seen only with bariatric surgery Oral formulations that eliminate the need for injections, improving access and patient preference Monthly or less frequent dosing options to improve adherence Enhanced understanding of how combining different hormonal pathways can optimize weight loss and metabolic health Weight Loss Medications in the Pipeline Researchers are evaluating several promising agents in late-stage clinical trials: Retatrutide : A triple GIP/GLP-1/glucagon receptor agonist that demonstrated weight loss of approximately 24% at 48 weeks on the 12 mg dose
Lifestyle modification remains fundamental, and patients should be encouraged to maintain healthy eating patterns, regular physical activity, and adequate hydration (individualised to their clinical situation, particularly for those with heart failure or kidney disease)
I would not change the dosage or stop a GLP1-RA in the setting of arrhythmias or palpitations, Dr
If you are on a GLP-1 like semaglutide and notice a change in your scent, it is often a temporary side effect of your body's adaptation
Key design elements that matter for interpreting the results
The main difference is that Wegovy is a standardized, FDA-approved commercial product, while compounded semaglutide is a custom-prepared medication made in regulated compounding pharmacies